These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties. Zittoun R; Marie JP; Brilhante D; Delmer A Haematol Blood Transfus; 1987; 30():45-9. PubMed ID: 3476378 [No Abstract] [Full Text] [Related]
3. Gelatinous transformation of marrow in a case of acute myelogenous leukemia post-chemotherapy. Feng CS Am J Hematol; 1991 Nov; 38(3):220-2. PubMed ID: 1951321 [TBL] [Abstract][Full Text] [Related]
4. A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia. Dahl GV; Kalwinsky DK; Mirro J; Look AT Haematol Blood Transfus; 1987; 30():83-7. PubMed ID: 3305227 [No Abstract] [Full Text] [Related]
5. Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia. Longu F; Fozza C; Dessì L; Longinotti M; Bonfigli S; Careddu MG; Coppola L; Giannico DB; Nieddu RM; Podda L; Pardini S; Dore F; Dore S; Sotgiu G Acta Haematol; 2017; 137(1):15-16. PubMed ID: 27806360 [No Abstract] [Full Text] [Related]
7. Therapy of acute myelogenous leukemia in adults. Borthakur G; Estey EE Cancer Treat Res; 2010; 145():257-71. PubMed ID: 20306256 [No Abstract] [Full Text] [Related]
8. Bone marrow fibre content in acute myeloid leukaemia before and after treatment. Islam A; Catovsky D; Goldman JM; Galton DA J Clin Pathol; 1984 Nov; 37(11):1259-63. PubMed ID: 6594351 [TBL] [Abstract][Full Text] [Related]
9. [A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse]. Shiga Y; Shichishima T; Aikawa K; Gotoh J; Furukawa T; Yamagiwa A; Ishibashi T; Maruyama Y Rinsho Ketsueki; 1994 May; 35(5):501-5. PubMed ID: 8028198 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease. Roberts MM; Juttner CA; To LB; Kimber RJ Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841 [TBL] [Abstract][Full Text] [Related]
11. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression. Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945 [TBL] [Abstract][Full Text] [Related]
12. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487 [TBL] [Abstract][Full Text] [Related]
13. Association between the secondary colony-plating efficiency of blast progenitors and the remission induction outcome of acute myeloblastic leukemia patients. Nara N Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1624-9. PubMed ID: 3247826 [No Abstract] [Full Text] [Related]
14. Second long-term remission achieved with low-dose Ara-C in children with relapsed acute nonlymphoblastic leukemia. Miniero R; Saracco P; Cordero di Montezemolo L; Fiandino G; Comelli A; Madon E Pediatr Hematol Oncol; 1987; 4(3):273-6. PubMed ID: 3152932 [No Abstract] [Full Text] [Related]